医学
初级预防
疾病
心肌梗塞
冠状动脉疾病
认知功能衰退
重症监护医学
他汀类
风险因素
临床试验
物理疗法
二级预防
队列
随机对照试验
糖尿病
队列研究
风险评估
梅德林
痴呆
心脏病
内科学
血管疾病
老年人
心血管事件
冲程(发动机)
死因
心血管健康
疾病管理
动脉粥样硬化性心血管疾病
作者
Toshie Tanaka,Yoshihiro Fukumoto
标识
DOI:10.1093/eurjpc/zwaf634
摘要
Abstract Age is a nonmodifiable risk factor for atherosclerosis and cardiovascular disease (CVD), with their prevalence increasing over time. Dyslipidaemia plays a key role in coronary artery disease (CAD) across all age groups, including older adults. However, limited evidence exists regarding the efficacy of lipid-lowering therapy, particularly statins, for primary prevention in older populations. This review underscores the significance of statins for primary prevention in older adults. The PROSPER study and similar trials demonstrated a 24% reduction in CAD mortality with statins, without notable cognitive or functional impairments. Similarly, the EWTOPIA 75 trial reported a 34% reduction in major cardiac events with ezetimibe, though benefits diminished in those aged >85 years. A meta-analysis revealed a 26% reduction in major vascular events per 1 mmol/L decrease in low-density lipoprotein cholesterol in older adults, with no heightened risks of cancer, haemorrhagic stroke, or cognitive decline. The Danish Contemporary Primary Prevention Cohort identified individuals aged 80–100 years as having the highest myocardial infarction risk, emphasizing the benefits of statin therapy in this group. Ongoing STAREE and PREVENTABLE trials aim to provide further evidence on statins for primary prevention in older adults. Effective CVD management in older populations should begin early, prioritizing a healthy lifestyle and addressing modifiable risk factors. Statin therapy should not be discontinued based on age alone and requires careful consideration for individuals with established CVD.
科研通智能强力驱动
Strongly Powered by AbleSci AI